The Ozempic savings card pays at most $100 toward each 28-day fill. So the advertised $25 is what a patient pays only when a commercial plan already covers Ozempic and charges $125 or less. Everyone else is offered Novo Nordisk's self-pay price list instead. This page reads both halves from Novo's own terms, works the cap arithmetic, and sets out what differs from the Wegovy card.
Three Novo Nordisk documents were opened on 6 October 2026: the Diabetes Savings Offer conditions (one document covering Ozempic pens, Ozempic tablets and Rybelsus), the Ozempic enrolment page on NovoCare, and the savings page on ozempic.com. Novo reserves the right to end or alter the programme without notice. Nothing here is a view on whether Ozempic suits a particular person; that sits with a prescriber.
What the offer is, in two halves
| Commercial copay offer | Self-pay offer | |
|---|---|---|
| Who it is for | Commercial insurance that covers Ozempic | No coverage, coverage that excludes Ozempic, or paying outside insurance |
| Patient pays | As little as $25 | $349 per pen (0.25/0.5 mg, 1 mg) · $499 (2 mg) · $199 new-patient intro · $149–$299 tablets |
| Most the card pays | $100 per 28-day fill · $200 per 2 fills · $300 per 3 fills | — (a fixed price, not a subsidy) |
| Government insurance | Excluded | Allowed only outside the insurance, with no reimbursement |
| Forms named in the terms | Injection and tablets | Injection and tablets |
List price, the per-milligram comparison with Wegovy and the wider ladder belong to what Ozempic costs; Novo's mail-order route is described on NovoCare Pharmacy. Below, only the card and its conditions.
The cap arithmetic: where $25 stops being $25
Novo's footnote on ozempic.com puts the injection offer in one line — $25 at best, "subject to a maximum savings of $100/month" — and the conditions define that month as 28 days, which for Ozempic means one carton containing a single multi-dose pen. Of the two numbers, the $100 ceiling is the one that usually sets the bill:
| Plan copay for one 28-day pen | Card pays | Patient pays |
|---|---|---|
| $40 | $15 | $25 |
| $125 | $100 | $25 |
| $175 | $100 | $75 |
| $300 | $100 | $200 |
| $600 | $100 | $500 |
| $1,000 (for example, early in a plan year before the deductible) | $100 | $900 |
Worked by glp1ledger from the $25 floor and $100 ceiling. Copay values are examples only; the real one depends on formulary tier, coinsurance and where the member stands against the deductible.
Everything turns on a $125 copay. Up to that point the patient's share lands at $25; past it, the patient simply gets $100 knocked off. A 90-day prescription triples the ceiling to $300, so a quarterly copay as high as $375 still nets to $25 — on two conditions spelled out in the Ozempic block: the prescription must be "written and dispensed for a 3-month supply", and the insurer has to cover a 3-month fill. The second condition is the plan's to grant, not Novo's.
Weekly dosing over 365 days needs roughly thirteen pens. Thirteen fills at the $100 ceiling put the card's theoretical yearly ceiling near $1,300 (our calculation). That figure only holds because the Ozempic conditions print no fill limit — Lilly's diabetes card, by contrast, stops at 13 fills and a stated annual sum.
The tablets now sold as Ozempic
Since the Rybelsus tablets were renamed (the history is on the Ozempic pill), the savings terms carry a separate block for Ozempic tablets 1.5 mg, 4 mg and 9 mg: the same $25, the same $100/$200/$300 caps, but a month "defined as 30 days" — one bottle of 30 tablets.
| Form | One "month" | Most the card pays per day of supply |
|---|---|---|
| Injection pen | 28 days | $3.57 |
| Tablets | 30 days | $3.33 |
Ozempic.com's savings page words the tablet offer as $25 "for any dose of Ozempic pill for up to a 3-month prescription", with the same $100 monthly cap in its footnote. The same document also keeps a $25 copay offer for Rybelsus 7 mg and 14 mg (and a 1-month-only version for 3 mg), effective 2 January 2026, for people still filling the old name.
How it differs from the Wegovy card
Ozempic and Wegovy are both semaglutide from the same manufacturer, but they are separate products with separate offers. Set against the Wegovy savings card (terms read 4 October 2026) and Lilly's Mounjaro savings card:
| Ozempic | Wegovy | Mounjaro | |
|---|---|---|---|
| Approved for | Type 2 diabetes (plus CV and kidney risk) | Weight management (plus CV, MASH) | Type 2 diabetes (plus CV since Aug 2026) |
| Monthly cap | $100 | $100 | $150 |
| $25 reached up to a copay of | $125 | $125 | $175 |
| Published yearly cap | none stated | none stated | $1,950 |
| Self-pay, highest pen | $499 (2 mg) | $399 (7.2 mg HD) | — |
| Self-pay, starting pen | $349 ($199 intro) | $349 ($199 intro) | — |
| Tablets in the offer | 1.5, 4, 9 mg | 1.5, 4, 9, 25 mg | — |
The detail that stands out: the highest Ozempic pen costs more on self-pay than the highest Wegovy pen — $499 for Ozempic 2 mg against $399 for Wegovy HD 7.2 mg in Novo's two price lists — even though the Wegovy pen holds the larger weekly dose. The copay card itself is identical in shape; the difference is in what Novo charges people who pay directly.
The clauses most summaries leave out
One commercial plan plus one government plan counts as government. Novo's enrolment form states that "individuals with both commercial and government-funded plans ARE considered patients with government insurance". A retiree with Medicare and an employer plan is outside the $25 offer. The form's note carves three groups back in: the Federal Employees Health Benefits programme, Affordable Care Act exchange plans and state-employee plans are not government programmes for this purpose.
Self-pay while on Medicare. The offer page says government-insured patients "are able to pay the self-pay price", outside the insurance. The self-pay terms then bind them not to seek reimbursement, not to count the cost toward a deductible, and to tell the insurer, if asked, that the medicine was bought outside the plan; pharmacies are told to keep the purchase out of Part D out-of-pocket totals. Medicare's own $50 GLP-1 Bridge does not include Ozempic — it covers weight-management prescriptions of three other products, as set out on the Medicare GLP-1 Bridge.
Accumulators, maximizers and alternate funding. A patient whose plan stops counting card payments toward the deductible (an accumulator) or sets the copay by what the card will pay (a maximizer) "will not be eligible for and agree not to use this savings program". The self-pay terms add a third exclusion: a plan that requires the patient to use the self-pay offer, or an alternate funding vendor, as a condition of covering Ozempic. Novo says it will monitor usage data and may reduce or stop savings "with or without notice".
One discount at a time. Pairing the Ozempic card with a discount-card price, another coupon or a self-pay discount is ruled out, and a discount card cannot stand in for insurance to unlock the $25 rate. Novo allows one combination only: an automatic manufacturer eVoucher that some pharmacies apply at the till.
The annual maximum that is mentioned but not stated. The accumulator clause allows Novo to reduce "your per claim maximum savings benefit and/or your annual maximum savings benefit". No annual figure, and no fill count, appears anywhere in the Ozempic offer details read for this page. Lilly's cards print both.
Forty-eight months, and nothing backdated. An activation is "valid for up to 48 months from date of enrollment", the prescription must carry a valid prescriber ID and be for an FDA-approved Ozempic indication, medication filled before enrolment cannot be reimbursed, and the offer is one per person, in the US and its territories, with availability in Massachusetts dependent on state law. ConnectiveRx administers it for Novo Nordisk.
Outside the card
A copay card only works on a claim the plan has already accepted. Where the plan refuses Ozempic or asks for prior authorization first, that step is described on GLP-1 prior authorization; options for people paying the full amount themselves are gathered on the cheapest way to get a GLP-1 without insurance. Novo also runs an income-tested free-medicine programme for people who are uninsured or on Medicare, which is a separate scheme from this card with its own application. And because the card is capped at $100, it helps least the patients with the highest copays.
Sources
Novo Nordisk, Diabetes Savings Offer Program — eligibility, restrictions and offer details for Ozempic, Ozempic tablets and Rybelsus (novocare.com, linked as savingscardeligibility.com), read 6 October 2026 · Novo Nordisk, Ozempic savings-offer page and enrolment form (novocare.com), read 6 October 2026 · Novo Nordisk, Save on Ozempic (ozempic.com), read 6 October 2026 · Novo Nordisk Wegovy and Eli Lilly Mounjaro card terms as recorded on this site's Wegovy (read 2026-10-04) and Mounjaro (read 2026-10-02) savings-card pages · CMS Medicare GLP-1 Bridge FAQ as recorded on this site's Bridge page (read 2026-09-19).